

Consumer ads unveiled

Campaign aims to bring dedicated pet owners back into the veterinary clinic.

page 10



September 2013 | Volume 44 | Number 9 | dvm360.com

Graduation levels hold the line

But the total number of new veterinary graduates could jump 18 percent by 2017. *By Julie Scheidegger*

The class of 2013 has tossed its caps and left the halls of academia—hopefully to jobs that fulfill hearts, minds and the demands of student loans. The numbers, no surprise, tell us that with each new class there are more veterinarians. But this year's gain was marginal.

Overall, class size increased just 1 percent from 2012 to 2013. Colorado State and Iowa State nabbed the top spot for largest graduating class, with 141 students. Although the University of Missouri increased class size the most, with a 46 percent jump, the University of Tennessee saw a decrease of 17 percent. Tuition costs varied from a pricey \$303,133 all-in at private Western University to a comparatively affordable Iowa State at approximately \$36,873 for an in-state student's four years of just tuition and fees.

Yet it may be the early statistics on the class of 2017 to note most closely. Based on schools reporting, the number of veterinary graduates in four years is poised to jump 18 percent from this year's total. It looks like only six of the now 30 accredited U.S. veterinary colleges will have class sizes under 100 students.

See page 18

How veterinary medicine can *save* the *world*

PART 1: CURING DISEASE

In the next few issues of *dvm360*, we're taking a close look at how veterinary medicine benefits people, not just animals. In this first installment, we meet a 'translational' (cross-species) researcher who's in the process of revolutionizing orthopedic medicine—for people and pets. *By John Lofflin*



Dr. James Cook of the University of Missouri holds a vial containing orthopedic donor tissue stored in a special fluid. The preservative, which he helped develop, keeps donor tissue healthy for two months, compared to the more traditional 30-day window. This means less wasted tissue.

The pain never stops. It bites when you sit. It bites when you stand. It bites when you climb the stairs, push in the clutch, bend over to pick up a piece of paper. It even bites when you lie down and try to sleep at night.

When your orthopedist slaps the x-ray up on the wall and describes the situation as "bone-on-bone," you know exactly what the words mean.

They mean somewhere down the road, your knee joints or hip balls will be sawed off and replaced with plastic or titanium. Yes, titanium joints are beautifully machined to tolerances representing the best of what the human mind can engineer. And if all goes well and you do the rehabilitation work, you'll get relief from the pain—at least for as long as these devices last.

See page 22



Barnyard hilarity with Dr. Obenski

page 7



Nemo the pig gets chemo at Cornell

page 12



Financial secrets for new graduates

page 35



The ultimate practice killer

page 48

How veterinary medicine can save the world

> Continued from page 1

But what if there were a better way? What if those replacement parts could be living tissue? Better yet, what if the deterioration was caught early and your orthopedist started a regenerative process rendering implants unnecessary?

Those living tissue replacements are being tested today in the lab and the clinic, and if someday they come to a knee or a hip near you, you can thank a dog ... and a veterinarian.

Driven to help knees from the age of 5

James (Jimi) L. Cook, DVM, PhD, DACVS, DACVSMR, holds dual appointments in veterinary and human medicine at the University of Missouri in Columbia, Mo. On this particular morning he's in the process of moving his office. His dual appointment has been 75 percent in the veterinary school and 25 percent in

the medical school, but now the proportions have reversed and his new office will be a few long strides away in the medical building.

Cook heads a team of 30 colleagues who work in two labs, one biologic and one engineering, both under the umbrella of the Comparative Orthopaedic Laboratory (COL) at Missouri. Its motto: "Finding joint solutions." Cook has been searching for joint solutions in

dogs since he entered Mizzou's PhD program in the mid-1990s, always with the aim of helping their human counterparts.

In fact, Jimi Cook has been driven since the age of 5 to do something about the pain in human knees. In 1975, his grandfather, Robert B. Gordon, had just undergone knee surgery and the prescription for rehabilitation was bike riding. So every morning he took his grandson out for a spin.

"I became part of his rehab," Cook says. "We'd ride bicycles every morning. We'd talk about everything under the sun on those bike rides. In my mind we were trying to solve this arthritis problem with my grandfather."

The memory is bittersweet because his grandfather's arthritis was a constant battle between science and pain. A tennis player and water skier, Gordon had severe primary degenerative arthritis in both knees. His first surgeon implanted a pair of pound-on prostheses, which Cook still has in his office. It's not hard to imagine how a researcher holding those metal wedges in his hands might be driven to produce true replacements from living tissue.

"When I'm speaking around the world I ask the people in the crowd to hold up their hands if they would love to have metal or plastic parts in their joints," Cook says. "I say, 'Raise 'em up real high and keep 'em up.' And, of course, no one ever raises their hand, anywhere I've been. So, while metal and plastic are better than the alternative, they're not perfect. There's pain, rehabilitation, complications. Even if the surgery goes well, honestly, you're still limited in function. No orthopedic surgeon will tell you that after your knee is replaced you're going back to what you were doing before."

Seven additional surgeries were doubtless not what his grandfather envisioned either in the mid-1970s when he trusted his knees to his first surgeon. Gordon was, in Cook's words, a self-made man who rose from sweeping floors at Airetool Manufacturing to president of the company. He wasn't

Discover the Future of Digital Dental Radiography

COME SEE US AT
Booth 306

The benchmark in VET-dental imaging — CR 7 VET —



- Highest Resolution (12,5 µm)
- Scans intraoral sizes 0-4
- Special Rabbit-IPs available
- VET-dental Software
- Wireless model available – CR7 Plus
- Comes with 10 network licenses, 2 year warranty and iM3 support
- iM3 exclusive worldwide master distributor

Flexible, re-usable
image plates

iM3 Inc. USA

12414 NE 95th Street, Vancouver, WA 98682 USA

p 1800 664 6348 | f +1 360 254 2940 | e info@im3usa.com

www.im3vet.com

iM3
The Veterinary Dental Company

the sort to give in to disease; instead he started researching the journals. He found an article in *Scientific American* describing the pound-on procedure. Cook has a rendering of the magazine cover and his grandfather's handwritten notes in the margins on a plaque. "I think he may have been the fifth person in the country to have that surgery," Cook says. "It was still very rare."

Pioneering as the procedure was, and as helpful as the seven additional surgeries were—certainly preferable to a wheelchair, amputation or joint fusion—Gordon still had skin grafts and infection, leg length and loosening—"all the problems associated with metal and plastic," Cook says.

Much like his grandfather, people hear about what Cook is doing at Missouri and write him letters desperate for the latest advances. He puts them on a list that now numbers over a hundred. "They say, 'I'll sign any release you want me to sign; I'll fly you to Europe or China or

wherever you can do it.' And I say, 'I'm a veterinarian,' and they say, 'I don't care. I don't want metal or plastic. I want you to do it. I'll sign any release. I'll pay any amount of money.'"

The veterinary side of the equation

People aren't writing Cook just for the pain in their own knees and hips. They're bringing their dogs to the clinic—sometimes in a last-ditch effort—for live tissue implants and other advanced procedures in hopes of getting them back to work or back in the field.

Cook's team works with all kinds of working dogs: agility, search and rescue, military, police, hunting, service and field trial dogs. Last year Cook treated an elbow in a rescue dog using a Canine Unicompartmental Elbow (CUE) developed in the Missouri lab for Arthrex VetSystems. The dog, Lincoln, hadn't worked for more than a year when Cook implanted the living cartilage using the CUE medial resurfacing procedure. Lincoln passed his six-month checkup in early May and Cook got word he went to Moore, Okla., to help with the rescue operation after the massive tornado of May 20th. "He helped find some people and some bodies," Cook says. "That's pretty cool."

One particular field trial dog has become a staple of Cook's talks, a symbol of what can be done with live tissue and a key link to human applications. His name is Buddy and he was 7 years old at the time of the surgery. Cook opens the silver Mac on his

desk, clears away clutter from his office move, and quickly finds the video record of Buddy's recovery. The first video shows Buddy unable to put his left leg down even with the buoyancy of water on the underwater treadmill. He looks nothing like the athlete who had won field trials and become a favorite of his owner and trainer. Buddy had been subjected to four knee surgeries, the last of which removed both menisci. His whole countenance, Cook says, had degenerated. His owner read about the work Cook was doing at Missouri and decided to give Buddy one last chance.

"He was completely non-weight-bearing lame," Cook recalls. "His owner said, 'Listen, doc, I love this dog but this dog is miserable.'" Buddy had lost 15 pounds and, in Cook's estimation, was depressed. "Those dogs live to work," he says. "If they can't work, literally, they will not eat."

The owner told Cook, "I'm going to have to put him to sleep. Not because I don't care about him, but because I care about him too much. He can't live like this."

Cook explained that the procedure had been effective in research dogs and was being considered in human medicine but was not approved yet. The owner decided to give it a try. So Cook completely replaced Buddy's knee joint with cartilage, bone and menisci grown in the Missouri lab from organ donor grafts. In his clinic office today, three years later, Cook pushes the play button on the Mac and the video shows

Buddy "running like the wind," in Cook's words, across an open field, cutting and maneuvering like a halfback slicing through the line. Buddy's even back to winning field trials, Cook says, and he's passed all his checkups.

"I've shown this video all over the world," Cook says. "Every time I watch it—and I've shown it literally hundreds of times—I get goosebumps."

Buddy wasn't the first dog to have live tissue implants at Missouri. The first was a dog from Minnesota who received an implant seven years ago, and the elbow is still sturdy. Dr. Cook recently had two dogs in the clinic with biologic joints, and a third, from Vancouver, British Columbia, had been discharged the day before after a cartilage graft.

The cartilage graft is interesting because that procedure originated on the human side, Cook says. "So," he says, "it comes full circle."

Building bridges for dog and man

Medical research has long been stranded on a set of islands. On one island lived the bench researcher in pursuit of the secrets of pure science. On another lived the clinical researcher who waited years, even decades, for pure research to reach the application phase. And, of course, the veterinary researchers lived on their own islands, apart from their human medicine counterparts.

Since money is almost as critical to research as ideas, all of those islands were fighting for pieces of the same pie.

Find it all here.
dvm360
Cancer research
It's not just orthopedic medicine that utilizes dogs as a model for human disease; oncology does as well. Visit dvm360.com/caninecancer to learn more about these efforts.

10 ways researchers are studying diseases in dogs and humans

Research labs in veterinary schools everywhere are investigating diseases in dogs as they pursue healing both humans and pets. Here are 10 examples:

1. Researchers in the Comparative Oncology Program, part of the National Cancer Institute, are active in the development of new cancer fighting drugs.
2. Researchers in the University of Minnesota College of Veterinary Medicine are investigating gene therapy to fight osteosarcoma in children and dogs.
3. The Animal Cancer Center at Colorado State University is also studying a variety of human and canine cancers, including osteosarcoma.
4. Several research groups are studying brain

tumors in dogs as a means to understand how brain tumors can be better treated in humans.

5. Researchers at North Carolina State University are studying genes in dogs to understand which ones cause canine and human cancers.
6. Similarly, the Canine Comparative Oncology Genomics Consortium has developed a bank of 2,000 patient tissue and tumor specimens for seven cancer histologies.
7. Researchers at the Purdue College of Veterinary Medicine are reporting results of work on environmental risks for cancer, including exposure to herbicide-treated lawns. Such exposure has been

linked to higher risk of bladder cancer in dogs.

8. Researchers in the Comparative Neurology Program at the University of Missouri College of Veterinary Medicine are studying diseases of the nervous system. They report dogs with canine multiple system degeneration show symptoms similar to Parkinson's in humans.
9. Researchers at the University of Copenhagen are studying cognitive dysfunction in geriatric dogs, a disease they say shares characteristics with Alzheimer's.
10. Researchers at North Carolina State University are also studying activity levels of dogs with mild heart disease, informed by mobility issues in humans who have experienced similar issues.

Brief Summary of Prescribing Information

convenia®
(cefovecin sodium)

Antimicrobial for Subcutaneous Injection in Dogs and Cats Only

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS:

Dogs

CONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of *Staphylococcus intermedius* and *Streptococcus canis* (Group G).

Cats

CONVENIA is indicated for the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of *Pasteurella multocida*.

CONTRAINDICATIONS: CONVENIA is contraindicated in dogs and cats with known allergy to cefovecin or to β-lactam (penicillins and cephalosporins) group antimicrobials. Anaphylaxis has been reported with the use of this product in foreign market experience. If an allergic reaction or anaphylaxis occurs, CONVENIA should not be administered again and appropriate therapy should be instituted. Anaphylaxis may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids, intravenous antihistamine, corticosteroids, and airway management, as clinically indicated. Adverse reactions may require prolonged treatment due to the prolonged systemic drug clearance (65 days).

WARNINGS: Not for use in humans. Keep this and all drugs out of reach of children. Consult a physician in case of accidental human exposure. For subcutaneous use in dogs and cats only. Antimicrobial drugs, including penicillins and cephalosporins, can cause allergic reactions in sensitized individuals. To minimize the possibility of allergic reactions, those handling such antimicrobials, including cefovecin, are advised to avoid direct contact of the product with the skin and mucous membranes.

PRECAUTIONS: Prescribing antibacterial drugs in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to treated animals and may increase the risk of the development of drug-resistant animal pathogens.

The safe use of CONVENIA in dogs or cats less than 4 months of age and in breeding or lactating animals has not been determined. Safety has not been established for IM or IV administration. The long-term effects on injection sites have not been determined. CONVENIA is slowly eliminated from the body, approximately 65 days is needed to eliminate 97% of the administered dose from the body. Animals experiencing an adverse reaction may need to be monitored for this duration.

CONVENIA has been shown in an experimental *in vitro* system to result in an increase in free concentrations of carprofen, furosemide, doxycycline, and ketoconazole. Concurrent use of these or other drugs that have a high degree of protein-binding (e.g. NSAIDs, propofol, cardiac, anticonvulsant, and behavioral medications) may compete with cefovecin-binding and cause adverse reactions.

Positive direct Coombs' test results and false positive reactions for glucose in the urine have been reported during treatment with some cephalosporin antimicrobials. Cephalosporin antimicrobials may also cause falsely elevated urine protein determinations. Some antimicrobials, including cephalosporins, can cause lowered albumin values due to interference with certain testing methods.

Occasionally, cephalosporins and NSAIDs have been associated with myelotoxicity, thereby creating a toxic neutropenia⁴. Other hematological reactions seen with cephalosporins include neutropenia, anemia, hypoprothrombinemia, thrombocytopenia, prolonged prothrombin time (PT) and partial thromboplastin time (PTT), platelet dysfunction and transient increases in serum aminotransferases.

ADVERSE REACTIONS:

Dogs

A total of 320 dogs, ranging in age from 8 weeks to 19 years, were included in a field study safety analysis. Adverse reactions reported in dogs treated with CONVENIA and the active control are summarized in Table 2.

Table 2: Number of Dogs* with Adverse Reactions Reported During the Field Study with CONVENIA.

Adverse Reaction	CONVENIA (n=157)	Active Control (n=163)
Lethargy	2	7
Anorexia/Decreased Appetite	5	8
Vomiting	6	12
Diarrhea	6	7
Blood in Feces	1	2
Dehydration	0	1
Flatulence	1	0
Increased Borborygmi	1	0

*Some dogs may have experienced more than one adverse reaction or more than one occurrence of the same adverse reaction during the study.

Mild to moderate elevations in serum γ-glutamyl trans-ferase or serum alanine aminotransferase were noted post-treatment in several of the CONVENIA-treated dogs. No clinical abnormalities were noted with these findings.

One CONVENIA-treated dog in a separate field study experienced diarrhea post-treatment lasting 4 weeks. The diarrhea resolved.

Cats

A total of 291 cats, ranging in age from 2.4 months (1 cat) to 21 years, were included in the field study safety analysis. Adverse reactions reported in cats treated with CONVENIA and the active control are summarized in Table 3.

Table 3: Number of Cats* with Adverse Reactions Reported During the Field Study with CONVENIA.

Adverse Reaction	CONVENIA (n=157)	Active Control (n=163)
Vomiting	10	14
Diarrhea	7	26
Anorexia/Decreased Appetite	6	6
Lethargy	6	6
Hyper/Acting Strange	1	1
Inappropriate Urination	1	0

*Some cats may have experienced more than one adverse reaction or more than one occurrence of the same adverse reaction during the study.

Four CONVENIA cases had mildly elevated post-study ALT (1 case was elevated pre-study). No clinical abnormalities were noted with these findings.

Twenty-four CONVENIA cases had normal pre-study BUN values and elevated post-study BUN values (37–39 mg/dL post-study). There were 6 CONVENIA cases with normal pre- and mildly to moderately elevated post-study creatinine values. Two of these cases also had an elevated post-study BUN. No clinical abnormalities were noted with these findings.

One CONVENIA-treated cat in a separate field study experienced diarrhea post-treatment lasting 42 days. The diarrhea resolved.

FOREIGN MARKET EXPERIENCE: The following adverse events were reported voluntarily during post-approval use of the product in dogs and cats in foreign markets: death, tremors/ataxia, seizures, anaphylaxis, acute pulmonary edema, facial edema, injection site reactions (alopecia, scabs, necrosis, and erythema), hemolytic anemia, salivation, pruritus, lethargy, vomiting, diarrhea, and inappetance.

For a copy of the Material Safety Data Sheet, (MSDS) or to report a suspected adverse reaction call Zoetis Inc. at 1-888-963-8471.

STORAGE INFORMATION:

Store the powder and the reconstituted product in the original carton, refrigerated at 2° to 8° C (36° to 46° F). **Use the entire contents of the vial within 56 days of reconstitution.** PROTECT FROM LIGHT. After each use it is important to return the unused portion back to the refrigerator in the original carton. As with other cephalosporins, the color of the solution may vary from clear to amber at reconstitution and may darken over time. If stored as recommended, solution color does not adversely affect potency.

HOW SUPPLIED:

CONVENIA is available as a 10 mL multi-use vial containing 800 milligrams of cefovecin as a lyophilized cake.

NADA# 141-285, Approved by FDA

zoetis

Distributed by
Zoetis Inc.

Kalamazoo, MI 49007

January 2013
PAA035845A&P

NEWS | Cover story

Today, that’s changing. Bridges between islands are under construction in labs like Cook’s at Missouri. Bench research is reaching clinical researchers more quickly. And veterinary medicine is reaching out to human medicine even as human medicine reaches out to veterinary medicine. “I know this is a cliché and I apologize,” Cook says of the translational research paradigm, “but this is simply a win-win proposition for everybody.”

For example, veterinary researchers have long been cramped by an economic ceiling on their efforts. To win funding for a project, they must demonstrate the potential for human application.

“It’s just a dead, straight-on fact that funding is going to go toward human medicine,” Cook explains. “What’s cool is that we can leverage that funding to help canine patients. It’s there for the humans, we test it in the dogs, but we can also apply it safely and effectively to the dogs. We’re healing the species that we’ve developed this product through.”

Cook adds that some major human medical firms are now investing in veterinary applications as a result of the research. In fact, he says, Arthrex now has a veterinary division based on some of the research originating in his lab and honed in the clinic. “They’ve seen what it can do in the marketplace in the real world on the veterinary side,” Cook says.

At Missouri, the veterinary side and the medical side have grown closer across the past decade. Cook says one reason is simple proximity; it’s just an eight-minute walk across campus from the veterinary building to the medical facility. His team includes engineers, veterinarians, molecular biologists and medical doctors. Interaction between the veterinary side and the medical side happens weekly if not daily. The new department chair in orthopedic surgery, James P. Stannard, MD, he says, clearly understands how research on the veterinary side can make the university “the best in the world” on the human side.

The bridge between veterinary medicine and human medicine being built at Missouri began with a plan Cook sketched out with Keith Kenter, MD, in 1995 on a napkin at

Buckingham’s Smokehouse Bar-B-Q in Columbia. Kenter was a medical doctor at roughly the same stage in his career as Cook. Kenter has since moved to the University of Cincinnati, but their napkin-based plan to combine veterinary research with human applications has grown from a lab “the size of a closet” in 1998 to a multimillion-dollar operation. “It grew quicker and bigger than I ever imagined,” Cook says. “We found passionate people who are team players and—we always say—teams defeat individuals.”

Cook says a typical research question starts with a question: “What can’t you tell a patient today?” “The answer might be that I can’t replace their joints with biological tissues,” Cook says. “I can’t tell a patient he or she can go back to full function. Once we know the question, we put the science behind it.”

Then the research goes from the laboratory through an animal model for safety and testing. Most of the time, for Cook’s lab, the animal model is a dog. Then, via a long pathway with the FDA, researchers progress to human clinical testing and use. But in the meantime, canine patients directly benefit through clinical application.

The big question:
Why did it take so long to join forces?

Today, the synergies between veterinary medicine and human medicine seem obvious. Several products of Cook’s lab are already approved for humans. When the FDA approves living tissue joint replacements, which Cook says will likely take about seven years, the connections will be even more evident to the lay public. And, he says, the evidence most persuasive so far to the FDA has been his videos of Buddy running in the field. So why has it taken this long to build bridges between the veterinary and human research islands?

“The first-blush answer is that we didn’t realize that it was one medicine, one health,” Cook says. “When you just look at a cow and a human you automatically see there are differences—four stomachs in a cow comes immediately to mind. I think our tendency has been to look at the differences first instead of the

similarities. And to stop there.”

But canine knees, hips and elbows, it turns out, are excellent models for human joints. Cook finds another set of images on the silver Mac then turns the screen around. The first image is a pair of still images of two open knee joints. The second is a pair of videos of arthroscopic meniscus repair. “I tell people, one of these is a dog and one of these is a human. If I was mean, I’d make the audience tell me which one is which. This is the human knee,” he says, pointing to the image of the right. “This is the dog knee. You can see they are almost identical.” The arthroscopic videos, he says, are even more difficult to distinguish, so much so that even some orthopedists can’t tell the difference.

So the problems in dogs are the same and the treatments are the same, Dr. Cook says. Even the rehabilitation procedures have turned out to be the same. These similarities are more obvious, he says, where working dogs and canine athletes are concerned. With 2.5 million registered agility dogs, mobility problems have become more obvious, paralleling mobility problems in human athletes. Owners notice subtleties: The dog ticks the bar when he used to clear 20-inch jumps easily or refuses the A-frame twice before he agrees.

“It’s funny that it has taken so long,” Cook says, “because we’ve anthropomorphized everything else about dogs, everything from diet to emotions to car seats. Everything but the medical parts.”

He says the wide distribution of information made available by the Internet has also hastened bridge building, each side becoming more aware of what the other is investigating. And financial pressures also play a key role as medical firms and granting institutions seek ways to maximize research dollars by pushing harder for clinical applications of pure science.

“I think what’s cool about it is the reaching out, the bridging, is coming from both sides today,” he says. “It’s not veterinarians going over and begging at the doors of the MDs. Or vice versa. Not MDs coming in saying, ‘Please work with us, please do animal models.’ It’s really the realization that what we are doing is very similar.”

Have cultural differences between veterinarians and medical doctors also stood in the way?

“I think ‘cultural’ is probably the most polite way to put it,” Cook says. “I think there was the veterinarian feeling inferior at times and the MDs maybe

perpetuating that. But I think that’s starting to bridge, too. If you had to go span the gap by yourself, it would be intimidating. I’ve been blessed at Missouri. People have respected me sometimes more than I deserve.”

Walking down the hall to his biologic lab with the long, sure strides of a man who was once a professional water skier, Cook describes the similarities between dog and man and the realization of what a good research model the

dog is for human orthopedic medicine. As he turns the corner, he finishes the thought.

“When I’m under the drape, I don’t care whether it’s a four-legger or a two-legger,” he says. “I want to fix what’s wrong. And, I want to fix it better.” **dvm360**

John Lofflin is a freelance writer in Kansas City, Mo., with extensive experience writing about the veterinary profession.



DAILY NUTRITION MATTERS

FEED YOUR CAREER

One click at a time.



Earn up to **15.5 hours of CE credit** and gifts with *Daily Nutrition Matters*®, a self-paced, online program to increase your knowledge of dog and cat nutrition.

Learn more and get started at **DailyNutritionMatters.com**